1. Home
  2. Knowledge Base
  3. References
  4. Neuroendocrine and behavioral consequences of hyperglycemia in cancer

Neuroendocrine and behavioral consequences of hyperglycemia in cancer

Vasquez JH, Borniger JC (2020) Neuroendocrine and behavioral consequences of hyperglycemia in cancer. Endocrinology 161(5):bqaa047. doi: 10.1210/endocr/bqaa047

Summary: Ablation of norepinephrine containing projections to the arcuate (via Anti-DBH-SAP injections) alters AgRP and neuropeptide (NPY) concentrations, leading to impairments in hypoglycemic (glucoprivic) or ghrelin-induced feeding.

Usage: Anti-DBH-SAP (bilateral 42-ng intracranial injections) was used in rats to investigate the role of hindbrain catecholamine afferents in increased ARC NPY and AgRP gene expression.

See: Fraley GS et al. Immunolesion of norepinephrine and epinephrine afferents to medial hypothalamus alters basal and 2-deoxy-D-glucose-induced neuropeptide Y and agouti gene-related protein messenger ribonucleic acid expression in the arcuate nucleus. Endocrinology 144(1):75-83, 2003.

Related Products: Anti-DBH-SAP (Cat. #IT-03)

Browse Articles

Need Support?

Can't find what you're looking for? Contact us, we're here to help!